These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29187387)

  • 1. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.
    van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; de Boer RA; Asselbergs FW; Wajon EMCJ; Orsel JG; Boersma E; Hillege HL; Akkerhuis KM;
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29187387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure.
    van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; Orsel JG; Westenbrink BD; Brunner-la Rocca HP; van Miltenburg AJM; Boersma E; Hillege HL; Akkerhuis KM;
    J Am Coll Cardiol; 2017 Nov; 70(19):2378-2388. PubMed ID: 29096809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study.
    Wang H; Chen Q; Li Y; Jing X; Liang T; Yang J
    Acta Cardiol; 2017 Apr; 72(2):188-195. PubMed ID: 28597803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
    van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
    Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study.
    Bouwens E; Brankovic M; Mouthaan H; Baart S; Rizopoulos D; van Boven N; Caliskan K; Manintveld O; Germans T; van Ramshorst J; Umans V; Akkerhuis KM; Kardys I
    J Am Heart Assoc; 2019 Feb; 8(4):e009555. PubMed ID: 30760105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.
    Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A
    J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.
    Meijers WC; Januzzi JL; deFilippi C; Adourian AS; Shah SJ; van Veldhuisen DJ; de Boer RA
    Am Heart J; 2014 Jun; 167(6):853-60.e4. PubMed ID: 24890535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure.
    Gürgöze MT; van Vark LC; Baart SJ; Kardys I; Akkerhuis KM; Manintveld OC; Postmus D; Hillege HL; Lesman-Leegte I; Asselbergs FW; Brunner-la-Rocca HP; van den Bos EJ; Orsel JG; de Ridder SPJ; Pinto YM; Boersma E
    Circ Heart Fail; 2023 Jan; 16(1):e009526. PubMed ID: 36408685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
    van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
    J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
    Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
    Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.
    Cheng W; Maciej R; Thiele H; Büttner P
    ESC Heart Fail; 2024 Oct; 11(5):2566-2577. PubMed ID: 38698741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
    Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
    Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
    Srivatsan V; George M; Shanmugam E
    Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Demissei BG; Cotter G; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Severin TM; Wang Y; Qian M; Teerlink JR; Metra M; Davison BA; Voors AA
    Eur J Heart Fail; 2017 Aug; 19(8):1001-1010. PubMed ID: 28133908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure.
    Miró Ò; González de la Presa B; Herrero-Puente P; Fernández Bonifacio R; Möckel M; Mueller C; Casals G; Sandalinas S; Llorens P; Martín-Sánchez FJ; Jacob J; Bedini JL; Gil V
    Biomarkers; 2017 Dec; 22(8):731-739. PubMed ID: 28406038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.